What life sciences’ GxP culture can teach every regulated sector about compliance

I spent several years leading the move of a GxP-regulated life sciences SaaS platform from on-premises to cloud, across a nine-operating-company portfolio. Coming into that world from enterprise architecture in professional services, the thing that struck me wasn't the volume of documentation, which is real, but the underlying discipline it enforces: nothing gets built, changed or released without the evidence to prove it worked as intended, and the evidence is designed in from the start rather than reconstructed afterwards for an auditor. Financial services, telecoms and the public sector all have compliance regimes of their own. Very few of them have that particular habit, and it's the one worth borrowing.

"If it isn't documented, it didn't happen"

That's the oldest cliché in GxP training, and like most clichés it's survived because it's true and useful. The discipline isn't about generating paper for its own sake; it's about treating evidence of correctness as a first-class deliverable, produced at the same time as the thing it's evidence for, not reconstructed weeks later when a regulator or an auditor asks a question nobody thought to answer in real time. Most other regulated sectors treat audit evidence as an afterthought: something IT or compliance assembles retrospectively when a request lands. GxP treats the absence of that evidence as the actual failure, regardless of whether the underlying system worked correctly. A system that works but can't prove it worked is, for GxP purposes, not validated. That's a genuinely different standard, and it changes how you build things, not just how you file them afterwards.

Change control as a habit, not a gate

Every regulated sector has some version of change management. What GxP does differently is make change control a routine habit applied to everything, not a heavyweight process reserved for the changes someone decided in advance were risky. Every change to a validated system, however small, goes through an assessed, documented, approved path, and the assessment itself is what determines how much scrutiny it gets, not a manager's gut feel about whether this particular change "counts." That consistency is what makes the process trustworthy under audit: there's no category of change that quietly slipped through outside the record, because there's no path that bypasses the record in the first place.

Risk-based validation, not uniform validation

It's a myth that GxP means validating everything to the same exhaustive standard. The GAMP framework that underpins computer system validation in life sciences is explicitly risk-based: a spreadsheet used for informal calculation gets a lighter validation footprint than a system that directly controls a batch record or a patient-safety decision. The rigour scales with consequence, not with how impressive or unfamiliar the technology looks. That's a useful corrective in itself: the amount of governance attention a system gets should track what happens if it's wrong, not how new or unusual it seems to the people reviewing it.

That's the same proportionality principle that good AI governance needs, and that most first-generation AI policy gets backwards, applying uniform scrutiny to everything rather than concentrating it where the consequence of failure is actually severe. Life sciences worked this out with paper-based quality systems decades before anyone was governing machine learning models, and the underlying logic transfers directly: classify by consequence first, then scale the process to match, rather than writing one process and applying it to everything regardless of stakes.

Traceability: connecting the requirement to the proof

The other GxP habit worth stealing is the traceability matrix: every requirement links forward to the test that proves it was met, and every test links back to the requirement it was written to satisfy. Nothing gets built that isn't traceable to a stated need, and nothing is claimed to work without a specific piece of evidence showing it does. It sounds bureaucratic written down like that, but in practice it's the same discipline good software engineering already values in test-driven development; GxP just makes it a mandatory, auditable artefact rather than an optional good habit some teams keep and others drop under deadline pressure. When a regulator, or a board, or a customer's due-diligence team asks "how do you know this works," the traceability matrix is the difference between producing an answer in minutes and reconstructing one over several stressful days.

That matters well beyond validated software. Financial services model risk management asks a structurally identical question of every model: what was it built to do, what's the evidence it does that, and who signed off on the evidence. Telecoms data-sovereignty commitments ask the same shape of question about where data actually flows versus where a contract says it should. The vocabulary differs by sector; the underlying discipline, requirement, evidence, sign-off, does not.

Quality is a culture, not a department

The most transferable lesson isn't a specific control at all. It's where the accountability sits. In a mature GxP organisation, quality isn't a department that other teams route requests to and wait for a verdict; it's a set of habits every engineer, scientist and product owner is trained into and personally accountable for, with the quality function acting as an expert partner and final check rather than the sole owner of correctness. Compare that with how compliance often works in financial services or telecoms, where a central risk or compliance function is the only place accountability formally sits, and every other team's incentive is to get their work over the wall to that function as fast as possible and move on. That structure guarantees exactly the friction it's trying to prevent, because the people closest to the risk have the least personal stake in catching it early.

What this looks like applied outside life sciences

None of this requires importing pharmaceutical bureaucracy wholesale into a bank or a telco, and that would be a bad idea; GxP's specific forms exist for reasons specific to drug safety. What transfers is the underlying design pattern: build the evidence of correctness into the process as it happens rather than reconstructing it later, make change control a universal habit rather than a selectively applied gate, scale validation effort to actual risk rather than applying one standard to everything, and put quality accountability into the teams doing the work rather than isolating it in a department that can only react. Regulated sectors that are still treating compliance as something added at the end of delivery, rather than designed into how delivery happens, are solving the same problem life sciences solved thirty years ago, just without the benefit of having already done it.

← Back to Insights